The role of immunotherapies in advanced acral and mucosal melanoma

Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands, discusses treatment options for patients with advanced acral and mucosal melanomas. With significantly higher prevalence in Asian populations, these melanomas have a low mutational burden, meaning they are more difficult to treat, generally responding poorly to checkpoint inhibitors. Whilst combined chemotherapy has shown some improvement in survival outcomes, the most promising advancement is the combination of immune checkpoint inhibitors with tyrosine kinase inhibitors (TKIs) and tumor infiltrating lymphocyte (TIL) therapy in both mucosal and acral carcinomas. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.